Developer docs
API playgroundTry for free, no card

Search company profiles

Hycor Biomedical

Full company profile

uuid00025m8

Namestring
Hycor Biomedical
Legal namestring
HYCOR Biomedical LLC
Company typeenum
Private
Founded yearint
1981
Descriptiontext

Hycor Biomedical (HYCOR Biomedical LLC) is a US-based in vitro diagnostics manufacturer headquartered in Garden Grove, California, founded in 1981 and operating with 51-100 employees. The company specializes in allergy and autoimmune diagnostic products for clinical laboratories, hospitals, and doctors' offices worldwide, with its flagship NOVEOS system representing the first major technological innovation in routine allergy diagnostics in approximately 20 years. NOVEOS is a microbead-based IgE antibody assay platform using chemiluminescent detection with a heterogeneous assay design that avoids biotin and cross-reactive carbohydrate determinant (CCD) interference, requires only 4 microliters of sample per test, and runs liquid ready-to-use reagents with automated walk-away capabilities. The company also markets legacy HYTEC and AUTOSTAT product lines.

Hycor monetizes through a combination of NOVEOS instrument sales, recurring specific IgE (sIgE) and component-resolved diagnostic (CRD) reagents across an allergen menu of 200+ assays (CE-marked for Europe), and service agreements for instrument maintenance and customer support. Go-to-market combines direct enterprise sales via a "Book A Demo" channel with regional distributor networks, particularly across Europe where the company maintains localized websites for German, French, and Spanish-speaking markets. Distribution is supported by scientific content marketing including peer-reviewed publications, webinars, white papers, and conference posters.

Hycor received FDA 510(k) clearance for NOVEOS in December 2018 and CE mark for the EU the same year, establishing regulatory footholds in the two largest markets. The company has raised approximately $89.6M across five disclosed funding rounds from 2017 through 2022 and operates as a privately held entity with no public listing. Key scientific partners include Johns Hopkins University School of Medicine (Dr. Robert Hamilton) and European GTM partner Axonlab. The company's competitive positioning emphasizes interference avoidance, miniaturized sample requirements, and laboratory workflow efficiency against established allergy diagnostic platforms such as Thermo Fisher's ImmunoCAP.

Short descriptiontext

Hycor Biomedical is a US-based in vitro diagnostics manufacturer specializing in allergy and autoimmune testing. Its flagship NOVEOS microbead-based IgE assay platform serves clinical laboratories, hospitals, and doctors' offices worldwide, with FDA and CE-marked products across a 200+ allergen menu.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersGarden Grove, United States
HQ citystring
Garden Grove
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro diagnostics, allergy testing, IgE antibody assays, allergen component diagnostics, clinical laboratory instruments
Industry3 codes
PRIMARYHLAHAAAK
Autoimmune, Allergy & Specialized Immunology Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
In Vitro Allergy Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1NOVEOS Allergy Testing System
TypeHardware Sales
Description

Sale of the NOVEOS instrument system and associated specific IgE (sIgE) assays for allergy diagnostics in clinical laboratories, hospitals, and doctors' offices.

hycorbiomedical.com
2Specific IgE Assay Reagents
TypeOne Time License
Description

Sale of specific IgE allergen assays including extract-based and component-resolved diagnostics (CRD) reagents. The company offers over 200 allergens with CE mark for Europe.

hycorbiomedical.com
3HYTEC and AUTOSTAT Brands
TypeOne Time License
Description

Sale of legacy HYTEC and AUTOSTAT brand products for allergy and autoimmune testing used in clinical laboratories worldwide.

hycorbiomedical.com
4Service Agreements
TypeSubscription Recurring
Description

Service agreements and technical support for instrument maintenance and customer care.

hycorbiomedical.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1NOVEOS
Description

Modern allergy testing immunoassay system using microparticle technology with 4μL sample requirement and reduced interference from biotin and CCD structures.

hycorbiomedical.com
+2 more records
Core offering1 text field

Hycor Biomedical manufactures and sells the NOVEOS in vitro allergy testing system, a microbead-based IgE antibody assay analyzer requiring only 4 µL of sample per test, together with a menu of more than 200 specific IgE allergen assays and component-resolved diagnostics (CRD) reagents. The system uses chemiluminescent detection and a heterogeneous assay design that avoids biotin and CCD interference, and is sold with service agreements to clinical laboratories, hospitals, and doctors' offices worldwide alongside the legacy HYTEC allergy and AUTOSTAT autoimmune product lines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • NOVEOS and ImmunoCAP have similar performances for diagnosing food allergies
+1 more record
Product overview1 text field

Hycor Biomedical offers a portfolio of in vitro diagnostic products for allergy and autoimmune testing. The primary product is the NOVEOS System, a modern immunoassay analyzer using proprietary microbead-based technology for specific IgE (sIgE) and total IgE testing. The NOVEOS system features a 4 µL sample requirement and proprietary interference avoidance mechanisms. Supporting product lines include HYTEC and AUTOSTAT brands. The company provides an extensive allergen menu with over 200 specific IgE assays and component-resolved diagnostics through the NOVEOS platform.

Product and service5 records
1NOVEOS Allergy Testing System
CategoryIn Vitro Diagnostics Instrument
Description

A modern allergy testing immunoassay analyzer using proprietary microbead-based IgE antibody assay technology with chemiluminescent detection for specific IgE (sIgE) and total IgE testing. Requires only 4 µL sample volume, avoids biotin and CCD interferences through heterogeneous assay design, and runs liquid ready-to-use reagents with automated walk-away capability for clinical laboratories, hospitals, and doctors' offices.

2NOVEOS Specific IgE Allergen Assays
CategoryDiagnostic Reagents / Assay Kits
Description

Specific IgE allergen test assays for use on the NOVEOS system, covering multiple allergen categories including mites, epidermal and animal proteins, foods, and molds. Over 200 allergens available with CE mark for Europe, offered as both extract-based and component-resolved diagnostics reagents.

3NOVEOS Allergen Component Testing (CRD)
CategoryDiagnostic Reagents / Assay Kits
Description

Component-resolved diagnostics (CRD) using molecular cloning techniques to create recombinant allergen components, enabling improved molecular-level allergy diagnosis particularly for complex cases such as mold allergy. For use on the NOVEOS platform.

4HYTEC Allergy Testing Products
CategoryIn Vitro Diagnostic Test Kits
Description

Legacy brand of allergy in vitro diagnostic products used in clinical laboratories, hospitals, and doctors' offices worldwide. Part of Hycor Biomedical's long-standing allergy testing portfolio alongside NOVEOS.

5AUTOSTAT Autoimmune Testing Products
CategoryIn Vitro Diagnostic Test Kits
Description

Legacy brand of autoimmune in vitro diagnostic test kits used in clinical laboratories worldwide. Part of Hycor Biomedical's diagnostic product portfolio addressing autoimmune disease testing alongside its allergy franchise.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-12-19
Description

Dr. Robert G. Hamilton, Ph.D., D.ABMLI, Professor of Medicine and Pathology at Johns Hopkins University School of Medicine provided expert commentary on NOVEOS technology as a novel diagnostic testing option with unique small sample size requirements for identifying sensitization in patients suspected of having allergic disease.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Axonlab partnered with HYCOR to present webinars on advancements in specific IgE testing, featuring expert speakers including Dr. Robert Hamilton and PD Dr. Skevaki. Webinar focused on evidence supporting NOVEOS as a new standard in allergy diagnostics.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Company provides educational resources and scientific literature for healthcare professionals, including allergy testing information and product insights to support accurate diagnosis and effective patient management.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Roche's cobas immunoassay platform competes in the clinical lab allergy testing market with broad menu coverage. A diversified incumbent with global reach and deep clinical laboratory relationships overlapping Hycor's customer base.

2Beckman Coulter (Danaher)
TypeBroad incumbent
Description

Beckman Coulter offers the Access and DxI immunoassay platforms that include allergy and autoimmune testing menus. A broad incumbent serving the same clinical laboratory customers that Hycor targets with NOVEOS.

TypeDirect peer
Description

EUROIMMUN is a leading specialty diagnostics manufacturer for autoimmune and allergy testing using immunoassay and immunofluorescence technologies. Highly comparable to Hycor's portfolio across the autoimmune (AUTOSTAT) line and allergy IgE assays.

TypeRegional player
Description

Stallergenes Greer is a global allergy-focused company (headquartered in Europe) that primarily provides allergen immunotherapy products, but also develops allergy diagnostics. Comparable focus on the allergy domain and clinical end users, with regional (European) concentration overlapping Hycor's EU footprint.

5Inova Diagnostics
TypeDirect peer
Description

Inova Diagnostics (a Werfen company) specializes in autoimmune disease diagnostics using immunoassay and immunofluorescence technologies. Directly comparable to Hycor's AUTOSTAT autoimmune product line and overlap in clinical lab end users.

TypeEmerging player
Description

Bühlmann Laboratories is a Swiss specialty diagnostics company focused on allergy, autoimmune, and inflammatory bowel disease testing using ELISA and immunoassay technologies. Comparable niche specialty IVD player targeting similar clinical lab end users, though smaller scale than Hycor.

TypeDirect peer
Description

Thermo Fisher's ImmunoCAP is the dominant specific IgE (sIgE) allergy diagnostics platform globally. It is Hycor's primary benchmark and direct competitor in routine clinical allergy blood testing, as evidenced by NOVEOS comparison studies published in peer-reviewed journals.

TypeBroad incumbent
Description

Bio-Rad is a diversified life science and clinical diagnostics company with significant presence in immunoassay instruments, quality controls, and autoimmune/allergy testing reagents. It serves similar clinical laboratory customers with broader portfolio depth than Hycor.

TypeBroad incumbent
Description

Siemens Healthineers offers the IMMULITE and Atellica immunoassay platforms that compete for clinical lab allergy and autoimmune testing workloads. A broad incumbent with global commercial reach overlapping Hycor's hospital and reference lab customer base.

10Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's Alinity and ARCHITECT immunoassay platforms compete in clinical lab allergy and autoimmune testing globally. A diversified incumbent with extensive installed base and broad menu across Hycor's addressable workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hycor Biomedical

In Vitro Allergy Diagnosticshycorbiomedical.com

Hycor Biomedical is a US-based in vitro diagnostics manufacturer specializing in allergy and autoimmune testing. Its flagship NOVEOS microbead-based IgE assay platform serves clinical laboratories, hospitals, and doctors' offices worldwide, with FDA and CE-marked products across a 200+ allergen menu.

What Hycor Biomedical does

Hycor Biomedical (HYCOR Biomedical LLC) is a US-based in vitro diagnostics manufacturer headquartered in Garden Grove, California, founded in 1981 and operating with 51-100 employees. The company specializes in allergy and autoimmune diagnostic products for clinical laboratories, hospitals, and doctors' offices worldwide, with its flagship NOVEOS system representing the first major technological innovation in routine allergy diagnostics in approximately 20 years. NOVEOS is a microbead-based IgE antibody assay platform using chemiluminescent detection with a heterogeneous assay design that avoids biotin and cross-reactive carbohydrate determinant (CCD) interference, requires only 4 microliters of sample per test, and runs liquid ready-to-use reagents with automated walk-away capabilities. The company also markets legacy HYTEC and AUTOSTAT product lines.

Hycor monetizes through a combination of NOVEOS instrument sales, recurring specific IgE (sIgE) and component-resolved diagnostic (CRD) reagents across an allergen menu of 200+ assays (CE-marked for Europe), and service agreements for instrument maintenance and customer support. Go-to-market combines direct enterprise sales via a "Book A Demo" channel with regional distributor networks, particularly across Europe where the company maintains localized websites for German, French, and Spanish-speaking markets. Distribution is supported by scientific content marketing including peer-reviewed publications, webinars, white papers, and conference posters.

Hycor received FDA 510(k) clearance for NOVEOS in December 2018 and CE mark for the EU the same year, establishing regulatory footholds in the two largest markets. The company has raised approximately $89.6M across five disclosed funding rounds from 2017 through 2022 and operates as a privately held entity with no public listing. Key scientific partners include Johns Hopkins University School of Medicine (Dr. Robert Hamilton) and European GTM partner Axonlab. The company's competitive positioning emphasizes interference avoidance, miniaturized sample requirements, and laboratory workflow efficiency against established allergy diagnostic platforms such as Thermo Fisher's ImmunoCAP.

Hycor Biomedical firmographics

Firmographics
Name
Hycor Biomedical
Legal name
HYCOR Biomedical LLC
Website
https://hycorbiomedical.com
Company type
Private
Founded year
1981
Operating status
Operating
Headcount range
101–250 employees
Short description
Hycor Biomedical is a US-based in vitro diagnostics manufacturer specializing in allergy and autoimmune testing. Its flagship NOVEOS microbead-based IgE assay platform serves clinical laboratories, hospitals, and doctors' offices worldwide, with FDA and CE-marked products across a 200+ allergen menu.
Ownership category
akta.pro rank

Hycor Biomedical industry classification

Industry
Product category
In Vitro Allergy Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAAAK
Autoimmune, Allergy & Specialized Immunology Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics

Keywords

  • In vitro diagnostics
  • Allergy testing
  • IgE antibody assays
  • Allergen component diagnostics
  • Clinical laboratory instruments

Where Hycor Biomedical is headquartered

Location

Headquarters

HQ city
Garden Grove
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Hycor Biomedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. NOVEOS Allergy Testing System: Sale of the NOVEOS instrument system and associated specific IgE (sIgE) assays for allergy diagnostics in clinical laboratories, hospitals, and doctors' offices.
  2. Specific IgE Assay Reagents: Sale of specific IgE allergen assays including extract-based and component-resolved diagnostics (CRD) reagents. The company offers over 200 allergens with CE mark for Europe.
  3. HYTEC and AUTOSTAT Brands: Sale of legacy HYTEC and AUTOSTAT brand products for allergy and autoimmune testing used in clinical laboratories worldwide.
  4. Service Agreements: Service agreements and technical support for instrument maintenance and customer care.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Hycor Biomedical product offering

Product offering

Core offering

Hycor Biomedical manufactures and sells the NOVEOS in vitro allergy testing system, a microbead-based IgE antibody assay analyzer requiring only 4 µL of sample per test, together with a menu of more than 200 specific IgE allergen assays and component-resolved diagnostics (CRD) reagents. The system uses chemiluminescent detection and a heterogeneous assay design that avoids biotin and CCD interference, and is sold with service agreements to clinical laboratories, hospitals, and doctors' offices worldwide alongside the legacy HYTEC allergy and AUTOSTAT autoimmune product lines.

Product overview

Hycor Biomedical offers a portfolio of in vitro diagnostic products for allergy and autoimmune testing. The primary product is the NOVEOS System, a modern immunoassay analyzer using proprietary microbead-based technology for specific IgE (sIgE) and total IgE testing. The NOVEOS system features a 4 µL sample requirement and proprietary interference avoidance mechanisms. Supporting product lines include HYTEC and AUTOSTAT brands. The company provides an extensive allergen menu with over 200 specific IgE assays and component-resolved diagnostics through the NOVEOS platform.

Differentiator

Problem solved

Functional benefit

Brands

  • NOVEOS: Modern allergy testing immunoassay system using microparticle technology with 4μL sample requirement and reduced interference from biotin and CCD structures.
  • HYTEC
  • AUTOSTAT

Products and services

  • NOVEOS Allergy Testing System A modern allergy testing immunoassay analyzer using proprietary microbead-based IgE antibody assay technology with chemiluminescent detection for specific IgE (sIgE) and total IgE testing. Requires only 4 µL sample volume, avoids biotin and CCD interferences through heterogeneous assay design, and runs liquid ready-to-use reagents with automated walk-away capability for clinical laboratories, hospitals, and doctors' offices.
  • NOVEOS Specific IgE Allergen Assays Specific IgE allergen test assays for use on the NOVEOS system, covering multiple allergen categories including mites, epidermal and animal proteins, foods, and molds. Over 200 allergens available with CE mark for Europe, offered as both extract-based and component-resolved diagnostics reagents.
  • NOVEOS Allergen Component Testing (CRD) Component-resolved diagnostics (CRD) using molecular cloning techniques to create recombinant allergen components, enabling improved molecular-level allergy diagnosis particularly for complex cases such as mold allergy. For use on the NOVEOS platform.
  • HYTEC Allergy Testing Products Legacy brand of allergy in vitro diagnostic products used in clinical laboratories, hospitals, and doctors' offices worldwide. Part of Hycor Biomedical's long-standing allergy testing portfolio alongside NOVEOS.
  • AUTOSTAT Autoimmune Testing Products Legacy brand of autoimmune in vitro diagnostic test kits used in clinical laboratories worldwide. Part of Hycor Biomedical's diagnostic product portfolio addressing autoimmune disease testing alongside its allergy franchise.

Quantifiable outcome

  • NOVEOS and ImmunoCAP have similar performances for diagnosing food allergies
  • +1 more outcomes

Companies that use Hycor Biomedical

Customer profile

Segments4 records

Ideal customer profiles3 records

Hycor Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Hycor Biomedical partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Johns Hopkins University School of MedicinecoreStrategic or Co-development Partner · 19 December 2018Dr. Robert G. Hamilton, Ph.D., D.ABMLI, Professor of Medicine and Pathology at Johns Hopkins University School of Medicine provided expert commentary on NOVEOS technology as a novel diagnostic testing option with unique small sample size requirements for identifying sensitization in patients suspected of having allergic disease.
  • AxonlabcoreGTM or Marketing PartnerAxonlab partnered with HYCOR to present webinars on advancements in specific IgE testing, featuring expert speakers including Dr. Robert Hamilton and PD Dr. Skevaki. Webinar focused on evidence supporting NOVEOS as a new standard in allergy diagnostics.
  • Healthcare Professional OrganizationsminorStrategic or Co-development PartnerCompany provides educational resources and scientific literature for healthcare professionals, including allergy testing information and product insights to support accurate diagnosis and effective patient management.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Hycor Biomedical competitors and assessment

Company assessment

Broad incumbents

  • Roche Diagnostics: Roche's cobas immunoassay platform competes in the clinical lab allergy testing market with broad menu coverage. A diversified incumbent with global reach and deep clinical laboratory relationships overlapping Hycor's customer base.
  • Beckman Coulter (Danaher): Beckman Coulter offers the Access and DxI immunoassay platforms that include allergy and autoimmune testing menus. A broad incumbent serving the same clinical laboratory customers that Hycor targets with NOVEOS.
  • Bio-Rad Laboratories: Bio-Rad is a diversified life science and clinical diagnostics company with significant presence in immunoassay instruments, quality controls, and autoimmune/allergy testing reagents. It serves similar clinical laboratory customers with broader portfolio depth than Hycor.
  • Siemens Healthineers: Siemens Healthineers offers the IMMULITE and Atellica immunoassay platforms that compete for clinical lab allergy and autoimmune testing workloads. A broad incumbent with global commercial reach overlapping Hycor's hospital and reference lab customer base.
  • Abbott Diagnostics: Abbott's Alinity and ARCHITECT immunoassay platforms compete in clinical lab allergy and autoimmune testing globally. A diversified incumbent with extensive installed base and broad menu across Hycor's addressable workflows.

Direct peers

  • EUROIMMUN (PerkinElmer/Revvity): EUROIMMUN is a leading specialty diagnostics manufacturer for autoimmune and allergy testing using immunoassay and immunofluorescence technologies. Highly comparable to Hycor's portfolio across the autoimmune (AUTOSTAT) line and allergy IgE assays.
  • Inova Diagnostics: Inova Diagnostics (a Werfen company) specializes in autoimmune disease diagnostics using immunoassay and immunofluorescence technologies. Directly comparable to Hycor's AUTOSTAT autoimmune product line and overlap in clinical lab end users.
  • Thermo Fisher Scientific (ImmunoCAP): Thermo Fisher's ImmunoCAP is the dominant specific IgE (sIgE) allergy diagnostics platform globally. It is Hycor's primary benchmark and direct competitor in routine clinical allergy blood testing, as evidenced by NOVEOS comparison studies published in peer-reviewed journals.

Regional players

  • Stallergenes Greer: Stallergenes Greer is a global allergy-focused company (headquartered in Europe) that primarily provides allergen immunotherapy products, but also develops allergy diagnostics. Comparable focus on the allergy domain and clinical end users, with regional (European) concentration overlapping Hycor's EU footprint.

Emerging players

  • Bühlmann Laboratories: Bühlmann Laboratories is a Swiss specialty diagnostics company focused on allergy, autoimmune, and inflammatory bowel disease testing using ELISA and immunoassay technologies. Comparable niche specialty IVD player targeting similar clinical lab end users, though smaller scale than Hycor.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Hycor Biomedical social profiles

Digital presence

Hycor Biomedical compliance and trust

Trust signal

Compliance2 records

Hycor Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hycor Biomedical leadership team

Management profile

Number of profiles

Profiles3 records

Hycor Biomedical subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Hycor Biomedical funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hycor Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hycor Biomedical

What does Hycor Biomedical do?

Hycor Biomedical manufactures and sells the NOVEOS in vitro allergy testing system, a microbead-based IgE antibody assay analyzer requiring only 4 µL of sample per test, together with a menu of more than 200 specific IgE allergen assays and component-resolved diagnostics (CRD) reagents. The system uses chemiluminescent detection and a heterogeneous assay design that avoids biotin and CCD interference, and is sold with service agreements to clinical laboratories, hospitals, and doctors' offices worldwide alongside the legacy HYTEC allergy and AUTOSTAT autoimmune product lines.

Is Hycor Biomedical a public or private company?

Hycor Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hycor Biomedical founded?

Hycor Biomedical was founded in 1981. It employs 101 to 250 people.

Where is Hycor Biomedical based?

Hycor Biomedical is headquartered in Garden Grove, United States, in the North America region.

How does Hycor Biomedical make money?

Four revenue lines are on record. NOVEOS Allergy Testing System is the primary driver. The others are specific IgE Assay Reagents, HYTEC and AUTOSTAT Brands and service Agreements.

Who are Hycor Biomedical's main competitors?

Broad incumbents on record are Roche Diagnostics, Beckman Coulter (Danaher), Bio-Rad Laboratories, Siemens Healthineers and Abbott Diagnostics. Direct peers are EUROIMMUN (PerkinElmer/Revvity), Inova Diagnostics and Thermo Fisher Scientific (ImmunoCAP). Stallergenes Greer is listed as a regional player. Bühlmann Laboratories is listed as an emerging player.

Does Hycor Biomedical have an API?

No public API is recorded for Hycor Biomedical.

What industry is Hycor Biomedical in?

Hycor Biomedical's product category is In Vitro Allergy Diagnostics. Its primary akta.pro industry code is HLAHAAAK, Autoimmune, Allergy & Specialized Immunology Diagnostics, with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireChangsha Haike, partenaire de HYCOR Biomedical, annonce l'enregistrement du système ALLEOS™ 2000 auprès de l'administration chinoise HMPAHYCOR Biomedical and its Chinese manufacturing partner Changsha Haike Biotechnology announced the registration of the ALLEOS 2000 allergy testing system with China's Hunan Medical Products Administration on August 4, 2020. The system leverages technology from HYCOR's NOVEOS platform and requires only 4μL of sample volume while delivering precise allergy test results. The companies expect to launch the ALLEOS 2000 instrument in China to improve patient care, particularly for pediatric populations where sample volume is limited.PR NewswireChangsha Haike, un socio de HYCOR Biomedical, anuncia el registro de China HMPA para el sistema ALLEOS™ 2000HYCOR Biomedical and its Chinese manufacturing partner Changsha Haike Biotechnology announced that the Hunan Medical Products Administration (HMPA) registered the ALLEOS 2000 allergy testing system on August 4, 2020. The system leverages technology from HYCOR's NOVEOS platform and requires only 4 ml of sample volume, making it particularly suitable for pediatric populations in China. Both companies expressed commitment to expanding allergy diagnostics in the Chinese market through this partnership.PR NewswireChangsha Haike, Partner von HYCOR Biomedical, gibt die Registrierung des Systems ALLEOS™ 2000 bei der chinesischen HMPA bekanntHYCOR Biomedical und sein chinesischer Produktionspartner Changsha Haike Biotechnology Co. Ltd. haben die Registrierung des Allergie-Testsystems ALLEOS 2000 bei der Hunan Medical Products Administration (HMPA) bekannt gegeben, die am 4. August 2020 wirksam wurde. Das System nutzt die für das NOVEOS-Plattform entwickelte Technologie und ermöglicht laut den Unternehmen einen automatisierten Hochdurchsatz-Betrieb mit nur 4 µl Probenvolumen. Die Registrierung markiert den Markteintritt von HYCOR im chinesischen In-vitro-Diagnostik-Sektor für Allergie-Tests, einem Markt, den das Unternehmen als strategisch sehr wichtig bezeichnet.PR NewswireHycor Biomedical pozyskuje pozwolenie FDA 510(k) w zakresie nowatorskiego rozwiązania testów alergicznych NOVEOS™Hycor Biomedical, a leading manufacturer of in vitro diagnostic products for allergy and autoimmune testing, has received 510(k) clearance from the U.S. Food and Drug Administration for its new NOVEOS allergy testing system. The system, utilizing micro particles, chemiluminescence, and liquid-ready reagents, represents the first new technology introduced in routine allergy testing laboratories in over 20 years, offering benefits including significantly reduced sample size, decreased blood interference, increased accuracy, and extended sample wait times. The company has also obtained clearance for the first Specific IgE (sIgE) test detecting dust mites and is focusing on developing additional tests to provide customers with a comprehensive testing panel.PR NewswireHycor Biomedical erhält 510(k)-Zulassung der FDA für NOVEOS™, ein modernes AllergietestinstrumentHycor Biomedical, a global manufacturer of in-vitro diagnostic products for allergy and autoimmune testing, announced on December 19, 2018 that it received 510(k) clearance from the U.S. Food and Drug Administration for its NOVEOS allergy testing system. NOVEOS uses microparticle, chemiluminescent technology with liquid ready-to-use reagents and represents the first new technology for routine allergy testing in laboratories in 20 years, offering reduced sample volume, improved accuracy, and reduced variability. The company simultaneously received clearance for the first specific IgE assay targeting house dust mite allergen (D001) and plans to develop additional assays to expand its menu.PR NewswireHycor Biomedical Receives FDA 510(k) Clearance for NOVEOS™, Its Modern Allergy Testing InstrumentHycor Biomedical has received U.S. FDA 510(k) clearance for NOVEOS, its new allergy testing system that uses microparticle and chemiluminescence technology, representing the first new technology platform for routine allergy testing labs in over 20 years. The system offers significant improvements including reduced sample size requirements, decreased blood-based interferences, increased accuracy, and improved walk-away time for laboratory technicians. The company also received simultaneous clearance for a Dust Mite allergen assay and plans to expand the test menu with additional assays.PR NewswireHycor Biomedical recibe la aprobación 510(k) de la FDA para NOVEOS™, su moderno instrumento de pruebas para la alergiaHycor Biomedical has received FDA 510(k) approval for its new allergy testing system, NOVEOS. This approval signifies a major advancement in allergy diagnostics, incorporating innovative technologies to reduce sample size and improve precision. The company is also developing additional tests to expand its offerings in the allergy diagnostics market.PR NewswireСистема аллергической диагностики NOVEOS™ от Hycor Biomedical получила одобрение FDA по форме 510(k)Hycor Biomedical received FDA 510(k) clearance for its NOVEOS allergic diagnostic system and the first specific IgE (sIgE) assay for dust mite allergen (D001). The NOVEOS system represents the first entirely new technology in 20 years for standard laboratory allergy testing, using microparticles and chemiluminescence to address key laboratory challenges including reduced sample size, improved accuracy, and decreased hands-on time. The company is now developing additional assays to build a complete allergy testing panel.PR NewswireSpolečnost Hycor Biomedical získala povolení 510(k) úřadu FDA pro svůj moderní systém pro testování alergií NOVEOS™Hycor Biomedical, a manufacturer of in vitro diagnostic products for allergy and autoimmune testing, has received 510(k) clearance from the US Food and Drug Administration (FDA) for its NOVEOS allergy testing system. NOVEOS uses micro-particle and chemiluminescence technology, representing the first new platform introduced in routine allergy testing laboratories in over 20 years, and offers reduced sample size, improved accuracy, and shorter turnaround times compared to existing technologies. The company simultaneously received clearance for its first specific IgE (sIgE) assay targeting dust mite allergens (D001) and plans to expand the test menu further.PR NewswireSpoločnosť Hycor Biomedical získava povolenie 510(k) od FDA na moderný nástroj testovania na alergie NOVEOS™Hycor Biomedical, a manufacturer of in vitro diagnostic products for allergy and autoimmune testing based in Garden Grove, California, received FDA 510(k) clearance in December 2018 to market its new NOVEOS allergy testing system. NOVEOS is a microparticle-based chemiluminescence system and represents the first new technology for routine allergy testing in 20 years, addressing common laboratory challenges with reduced sample sizes, lower interference, and improved accuracy. The company has also received clearance for the first specific IgE (sIgE) test for dust mite allergens and is developing additional tests to expand its menu offering.